Huella digital
- 1 Perfiles similares
Colaboraciones y áreas de investigación principales de los últimos cinco años
-
Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction–Associated Steatohepatitis
Frias, J., Schmouder, R., Lawitz, E., Zhang, Y., Zhou, H., Badman, M. K., Ukomadu, C., Weiss, H. M., Zack, J., Yadav, B., Martic, M., Drakeford, C., Koo, P., Naoumov, N. V. & Greenbaum, L. E., mar 2026, En: Alimentary Pharmacology and Therapeutics. 63, 5, p. 637-647 11 p.Producción científica: Article › revisión exhaustiva
Acceso abierto3 !!Link opens in a new tab Citas (Scopus) -
Editorial: Combination Therapies for MASH: A Step Forward or More Complexity? Authors' Reply
Lawitz, E. & Greenbaum, L., mar 2026, En: Alimentary Pharmacology and Therapeutics. 63, 6, p. 905-906 2 p.Producción científica: Editorial › revisión exhaustiva
-
Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic Functions
Usansky, H., Au Yeung, S., Li, S., Marbury, T., Lawitz, E., Kayali, Z. & Stein, D. S., 2026, (Accepted/In press) En: Clinical Pharmacokinetics.Producción científica: Article › revisión exhaustiva
Acceso abierto -
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective
Younossi, Z. M., Razavi, H., Sherman, M., Allen, A. M., Anstee, Q. M., Cusi, K., Friedman, S. L., Lawitz, E., Lazarus, J. V., Schuppan, D., Romero-Gómez, M., Schattenberg, J. M., Vos, M. B., Wong, V. W. S., Ratziu, V., Hompesch, M., Sanyal, A. J. & Loomba, R., may 2025, En: Alimentary Pharmacology and Therapeutics. 61, 9, p. 1467-1478 12 p.Producción científica: Article › revisión exhaustiva
26 !!Link opens in a new tab Citas (Scopus) -
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials
Armisen, J., Rauschecker, M., Sarv, J., Liljeblad, M., Wernevik, L., Niazi, M., Knöchel, J., Eklund, O., Sandell, T., Sherwood, J., Bergenholm, L., Hallén, S., Wang, S., Kamble, P., Bhat, M., Maxvall, I., Wang, Y., Lee, R. G., Bhanot, S. & Guo, S. y 6 otros, , jul 2025, En: Journal of Hepatology. 83, 1, p. 31-42 12 p.Producción científica: Article › revisión exhaustiva
30 !!Link opens in a new tab Citas (Scopus)
Conjuntos de datos
-
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
Zoulim, F. (Creator), Moreno, C. (Creator), Lee, S. S. (Creator), Buggisch, P. (Creator), Horban, A. (Creator), Lawitz, E. (Creator), Corbett, C. (Creator), Lenz, O. (Creator), Fevery, B. (Creator), Verbinnen, T. (Creator), Shukla, U. (Creator) & Jessner, W. (Creator), Figshare, 2018
DOI: 10.6084/m9.figshare.c.3990051, https://figshare.com/collections/A_3-year_follow-up_study_after_treatment_with_simeprevir_in_combination_with_pegylated_interferon-_and_ribavirin_for_chronic_hepatitis_C_virus_infection/3990051
Dataset
-
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Feld, J. J. (Creator), Lawitz, E. (Creator), Nguyen, T. (Creator), Lalezari, J. (Creator), Hassanein, T. (Creator), Martin, P. (Creator), Han, S.-H. (Creator), Dieterich, D. (Creator), Giard, J.-M. (Creator), De La Rosa, G. (Creator), Ahmad, A. (Creator), Luo, E. (Creator), Conery, A. L. (Creator) & Adda, N. (Creator), SAGE Journals, 2022
DOI: 10.25384/sage.c.6301764, https://sage.figshare.com/collections/EDP-514_in_healthy_subjects_and_nucleos_t_ide_reverse_transcriptase_inhibitor-suppressed_patients_with_chronic_hepatitis_B/6301764
Dataset
-
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Feld, J. J. (Creator), Lawitz, E. (Creator), Nguyen, T. (Creator), Lalezari, J. (Creator), Hassanein, T. (Creator), Martin, P. (Creator), Han, S.-H. (Creator), Dieterich, D. (Creator), Giard, J.-M. (Creator), De La Rosa, G. (Creator), Ahmad, A. (Creator), Luo, E. (Creator), Conery, A. L. (Creator) & Adda, N. (Creator), SAGE Journals, 2022
DOI: 10.25384/sage.c.6301764.v1, https://sage.figshare.com/collections/EDP-514_in_healthy_subjects_and_nucleos_t_ide_reverse_transcriptase_inhibitor-suppressed_patients_with_chronic_hepatitis_B/6301764/1
Dataset
-
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Feld, J. J. (Creator), Lawitz, E. (Creator), Nguyen, T. (Creator), Lalezari, J. (Creator), Hassanein, T. (Creator), Martin, P. (Creator), Han, S.-H. (Creator), Dieterich, D. (Creator), Giard, J.-M. (Creator), De La Rosa, G. (Creator), Ahmad, A. (Creator), Luo, E. (Creator), Conery, A. L. (Creator) & Adda, N. (Creator), SAGE Journals, 2022
DOI: 10.25384/sage.c.6301764, https://sage.figshare.com/collections/EDP-514_in_healthy_subjects_and_nucleos_t_ide_reverse_transcriptase_inhibitor-suppressed_patients_with_chronic_hepatitis_B/6301764
Dataset
-
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Feld, J. J. (Creator), Lawitz, E. (Creator), Nguyen, T. (Creator), Lalezari, J. (Creator), Hassanein, T. (Creator), Martin, P. (Creator), Han, S.-H. (Creator), Dieterich, D. (Creator), Giard, J.-M. (Creator), De La Rosa, G. (Creator), Ahmad, A. (Creator), Luo, E. (Creator), Conery, A. L. (Creator) & Adda, N. (Creator), SAGE Journals, 2022
DOI: 10.25384/sage.c.6301764.v1, https://sage.figshare.com/collections/EDP-514_in_healthy_subjects_and_nucleos_t_ide_reverse_transcriptase_inhibitor-suppressed_patients_with_chronic_hepatitis_B/6301764/1
Dataset